Clinical Trials Browser

Phase 1/2 × Vaccines, DNA × 90 days × Clear all

NCT06631092 2026-02-20

Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer

Phase 1/2 Recruiting

Triple Negative Breast Neoplasms